Dasatinib Monohydrate Powder CAS 863127-77-9 Raw Materials

Related Attributes

Product details

Dasatinib Monohydrate Powder Usage and Synthesis.

Dasatinib Monohydrate, also known as DASA Tin IB, is an off-white to yellow solid chemical.

Dasatinib Monohydrate Powder is an antineoplastic agent, Dasatinib Monohydrate Raw Materials is clinically indicated for the treatment of adult patients with imatinib mesylate resistant, or intolerant, chronic myeloid leukaemia (CML) in the chronic, accelerated and acute phases (acute granulomatous and acute lytic). 

Dasatinib Monohydrate Raw Materials is clinically indicated for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in the chronic, accelerated and acute phases (acute granulomatous and acute lytic).

Uses and functions of Dasatinib Monohydrate Powder.

Dasatinib is intended for use in adult patients with all stages of chronic myeloid leukaemia (chronic, accelerated, lymphocytic-acute and myeloid-acute) who have been treated, including those who are resistant or intolerant to Imatinib mesylate/Gleevec. Dasatinib Monohydrate is an anti-cancer API intermediate/pharmaceutical intermediate

Pharmacological Effects of Dasatinib Monohydrate Powder.

Dasatinib (5 mg/kg and 50 mg/kg, qd×10d, 5 on-2 off) possesses potent antitumor activity and a high safety margin in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels[1]. Dasatinib (10 mg/kg) has a pharmacokinetic profile appropriate for continued advancement into in vivo efficacy studies. 

Dasatinib (10 mg/kg) demonstrates favorable half-lives (t1/2s) of 3.3 and 3.1 h for i.v. and oral, respectively. The oral bioavailability (Fpo) in this study is 27%[1]. 

Animal Model: Nude mice bearing K562 xenografts Dosage: 5 mg/kg and 50 mg/kg Administration: Oral administration on a 5 day on and 2 day off schedule. 

Result: Showed partial tumor regressions after one treatment cycle and complete disappearance of the tumor mass by the end of drug treatment. No toxicity (animal deaths, lack of weight gain) was observed. 

Animal Model: Sprague-Dawley Rats Dosage: 10 mg/kg (Pharmacokinetic Analysis) Administration: Oral and i.v. Result: Cmax of 13.2 and 0.5 μM for i.v. and oral, respectively.

Production method of Dasatinib Monohydrate Powder.

Why choose us?

HRK Factory

About Shipping